Laboratories

Back
Top > Laboratories > Internal Medicine > Hematology and Oncology

Internal MedicineHematology and Oncology

Introduction

Hematopoietic organs (bone marrow), blood vessels, blood, spleen, thymus, lymph nodes and other tissues form an extremely close network in the body, and play important roles in keeping vital activities. Blood is simple to collect and easy to handle in test tubes, and thus has been used as a subject for research since old times. In the Hematology and Oncology department, we are working intensely on our mission to elucidate the pathological conditions of patients and to develop and establish novel treatments for patients by using various techniques from fields such as cell biology, biochemistry, genetic engineering, molecular biology and drug development.
The department has achieved results in a wide range of advanced research fields, including analysis of molecular mechanisms related to the onset of leukemia and malignant lymphoma, development of novel molecular targeted therapies, overcoming drug resistance to molecularly targeted drugs, and transplant immunology to improve results in hematopoietic stem cell transplantation.
The department got its start when the hematology group of the former First Department of Internal Medicine became independent. The former First Department of Internal Medicine was established in the Taisho Era (1912-1926), with Professor Seizo Katsunuma, known as the founder of the Japanese Society of Hematology, serving as the first professor. He was succeeded by Prof. Susumu Hibino, Prof. Itsuro Sobue, Prof. Hidehiko Saito and Prof. Tomoki Naoe, and the department developed with a history and tradition not only in hematology, but in internal medicine.
In the university hospital, we are in charge of the hematology ward, working to treat hematological malignancies (e.g., leukemia, lymphoma, myeloma), hematopoietic disorders (e.g., aplastic anemia), coagulation disorders (hemophilia, von Willebrand disease, etc.), and other diseases. The department currently has 17 graduate students in the doctoral course. Many people study overseas after graduating from the program; currently 3 members are studying in the United States, 1 member are studying in Canada. Of the 32 members, 8 have studied in other countries.

Research Projects

The Department of Hematology and Oncology works closely with domestic and overseas laboratories to actively advance research in the following main areas.

(1) Clinical research group (Prof. Kiyoi, Prof. Hayakawa, Lecturer Terakura, Lecturer Ishikawa, Lecturer. Shimada, Hospital Lecturer. Ushijima, Assistant Prof. Hanajiri, Assistant Prof. Furukawa, Assistant Prof. Sato)

This clinical research group actively participates multi-center clinical trials to develop new treatment for hematological malignancies. We are a member of Japan Adult Leukemia Study Group (JALSG) and the Japan Clinical Oncology Group (JCOG). And we also conduct multicenter research as a member of the Nagoya Blood and Marrow Transplantation Group (NBMTG), and nationwide retrospective studies in the Japan Society for Hematopoietic Cell Transplantation (JSHCT).

(2) Analyzing molecular pathogenesis/target therapy development group (Prof. Kiyoi, Lecturer Ishikawa, Lecturer. Shimada, Hospital Lecturer. Ushijima, Assistant Prof. Furukawa)

We investigate molecular pathology of hematological malignancies such as acute leukemia, myelodysplastic syndrome, and malignant lymphoma and develop novel therapies for them. We search for molecular targets for anti-cancer therapy through comprehensive gene analyses by next generation sequencer and analyses of patient-derived xenograft (PDX) that was established by transplanting patient tumor cells into mice. We also work together with pharmaceutical companies in the preclinical development of molecularly targeted drugs.

(3) Immunotherapy development group (Lecturer Terakura, Assistant Prof. Hanajiri)

Basic research in this group is focused on overcoming post-transplantation complications such as GVHD and viral infections, increasing the GVL effect, and developing of gene therapy using chimeric antigen receptor. We also aim to develop novel transplantation and immunotherapy through clinical research on “intra-bone marrow transplantation of cord blood” “application of MSC for transplantation” and “viral-specific CTL therapy”.

(4) Thrombosis and Hemostasis group (Blood Transfusion Dept.:Prof. Matsushita, Lecturer. Suzuki, Assistant Prof. Kanematsu, Assistant Prof. Okamoto)

This group studies the mechanisms of congenital and acquired bleeding disorders and thrombotic factors. We also develop and analyze original murine models which mimic human disorders, von Willebrand disease, MYH9 disorders and prothrombin disorders etc.

Faculty Members

FacultyPositionDepartment
Hitoshi KIYOI Professor Hematology and Oncology
Fumihiko HAYAKAWA Lecturer Hematology and Oncology
Seitaro TERAKURA Lecturer Hematology and Oncology
Yuichi ISHIKAWA Lecturer Hematology and Oncology
Kazuyuki SHIMADA Lecturer Hematology and Oncology
Yoko USHIJIMA Lecturer of hospital Hematology and Oncology
Ryo HANAJIRI Assistant Professor Hematology and Oncology
Katsuya FURUKAWA Assistant professor Center for Postgraduate Clinical Training and Career Development / Hematology and Oncology
Takahiko SATO Assistant Professor Hematology and Oncology

Bibliography

  • 2023
    1. Kato Koji、Fujii Nobuharu、Makita Shinichi、Goto Hideki、Kanda Junya、Shimada Kazuyuki、Akashi Koichi、Izutsu Koji、Teshima Takanori、Fukuda Natsuko、Sumitani Tokuhito、Nakamura Shota、Sumi Hiroyuki、Shimizu Shinji、Kakurai Yasuyuki、Yoshikawa Kenji、Tobinai Kensei、Usui Noriko、Hatake Kiyohiko.A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.International Journal of Hematology. 2023:117(3): 409-420.
    2. Wakamatsu M, Murata M, Kanda J, Fukushima K, Fukuda T, Najima Y, Katayama Y, Ozawa Y, Tanaka M, Kanda Y, Eto T, Takada S, Kako S, Uchida N, Kawakita T, Yoshiko H, Ichinohe T, Atsuta Y, Terakura S; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation.Int J Hematol.2023: 117(6):889-899.
    3. Shinobu Tsuzuki, Takahiko Yasuda, Hiroaki Goto, Naoko Maeda, Koshi Akahane, Takeshi Inukai, Hideyuki Yamamoto, Sivasundaram Karnan, Akinobu Ota, Toshinori Hyodo, Hiroyuki Konishi, Yoshitaka Hosokawa, Hitoshi Kiyoi, Fumihiko Hayakawa.BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia.Haematologica.2023: 1;108(2): 394-408.
    4. Naruko Suzuki, Nobuaki Suzuki, Yuka Kawaguchi, Shuichi Okamoto, Takeshi Kanematsu, Akira Katsumi, Atsuo Suzuki, Shogo Tamura, Tetsuhito Kojima , Hitoshi Kiyoi, Tadashi Matsushita.The usefulness of tranexamic acid for bleeding symptoms of chronic consumptive coagulopathy complicated by aortic disease: a single-institute, retrospective study of 14 patients.Thromb J.2023: 21(1): 10.
    5. Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, Sakamoto S, Watanabe A, Ohara K, Wang B, Xu H, Minagawa A, Hotta A, Woltjen K, Uemura Y, Kodama Y, Seno H, Nakatsura T, Tamada K, Kaneko S.Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells.Nat Biomed Eng.2023: 7(1): 24-27.
    6. Kurayoshi K, Takase Y, Ueno M, Ohta K, Fuse K, Ikeda S, Watanabe T, Nishida Y, Horike SI, Hosomichi K, Ishikawa Y, Tadokoro Y, Kobayashi M, Kasahara A, Jing Y, Shoulkamy MI, Meguro-Horike M, Kojima K, Kiyoi H, Sugiyama H, Nagase H, Tajima A, Hirao A. Targeting cis-regulatory elements of FOXO family is a novel therapeutic strategy for induction of leukemia cell differentiation.Cell Death Dis.2023: 14(9): 642.
    7. Ohbiki M, Ito Y, Inamoto Y, Miyamura K, Uchida N, Fukuda T, Fujiwara H, Nishida T, Hayashi M, Tanaka M, Kawakita T, Ikegame K, Katayama Y, Ara T, Ichinohe T, Kiyoi H, Matsuo K, Atsuta Y.Improved Long-Term Net Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies over Two Decades.Transplant Cell Ther.2023: 29(12): 768.e1-768.e10.
    8. Takagi E, Terakura S, Fujigaki H, Okamoto A, Miyao K, Sawa M, Morishita T, Goto T, Ozawa Y, Nishida T, Fukushima N, Ozeki K, Hanajiri R, Saito K, Murata M, Tomita A, Kiyoi H.Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts.Int J Hematol.2023: 118(4): 462-471.
    9. Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Taniguchi Y, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Kiyoi H, Matsumura I, Miyazaki Y.High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study.Hemasphere.2023: 7(6): e899.
    10. Nishiwaki S, Sugiura I, Sato T, Kobayashi M, Osaki M, Sawa M, Adachi Y, Okabe M, Saito S, Morishita T, Kohno A, Nishiyama T, Iida H, Kurahashi S, Kuwatsuka Y, Sugiyama D, Ito S, Nishikawa H, Kiyoi H.Autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia is safe but poses challenges for long-term maintenance of molecular remission: Results of the Auto-Ph17 study.EJHaem.2023: 4(2): 358-369.
    11. Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K.Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.Lancet Haematol.2023: 10(6): e419-e432.
    12. Kojima Y, Kawashima F, Yasuda T, Odaira K, Inagaki Y, Yamada C, Muraki A, Noura M, Okamoto S, Tamura S, Iwamoto E, Sanada M, Matsumura I, Miyazaki Y, Kojima T, Kiyoi H, Tsuzuki S, Hayakawa F.EBF1-JAK2 inhibits the PAX5 function through physical interaction with PAX5 and kinase activity.Int J Hematol.2023: 118(1): 65-74.
    13. Sahashi S, Shimada K, Takagi Y, Aoki T, Kunou S, Sakamoto A, Murase A, Furukawa K, Kagaya Y, Yamaga Y, Takai M, Tokuyama K, Shimada S, Nakamura S, Kiyoi H.Clinicopathological characteristics associated with the engraftment of patient lymphoma cells in NOG mice.Int J Hematol.2023: 118(2): 221-230.
    14. Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, Sakamoto S, Watanabe A, Ohara K, Wang B, Xu H, Minagawa A, Hotta A, Woltjen K, Uemura Y, Kodama Y, Seno H, Nakatsura T, Tamada K, Kaneko S.Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells.Nat Biomed Eng.2023: 7(1): 24-37.
    15. Wakamatsu M, Murata M, Kanda J, Fukushima K, Fukuda T, Najima Y, Katayama Y, Ozawa Y, Tanaka M, Kanda Y, Eto T, Takada S, Kako S, Uchida N, Kawakita T, Yoshiko H, Ichinohe T, Atsuta Y, Terakura S.Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation.Int J Hematol.2023: 117(6): 889-899.
    16. Hanajiri R, Furukawa K, Nakashima M, Ushijima Y, Shimada K, Ishikawa Y, Terakura S, Murata M, Kiyoi H.Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma.臨床血液.2023: 64(3) :163-174.
    17. Jo T, Arai Y, Kanda J, Kondo T, Ikegame K, Uchida N, Doki N, Fukuda T, Ozawa Y, Tanaka M, Ara T, Kuriyama T, Katayama Y, Kawakita T, Kanda Y, Onizuka M, Ichinohe T, Atsuta Y, Terakura S.A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Commun Med (Lond).2023: 3(1): 67.
    18. Shimomura Y, Komukai S, Kitamura T, Sobue T, Akahoshi Y, Kanda J, Ohigashi H, Nakamae H, Hiramoto N, Nagafuji K, Tanaka T, Eto T, Ota S, Maruyama Y, Akasaka T, Matsuoka KI, Mori Y, Fukuda T, Atsuta Y, Terakura S.Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide.Bone Marrow Transplant.2023: 59(1): 66-75.
    19. Terakura S.Challenges and prospects for CAR-T therapy.臨床血液.2023: 64(11): 1470-1476.
    20. Terakura S.Selection strategy for graft source in 2023.臨床血液.2023: 64(9): 1152-1157.
    21. Naoe T, Saito A, Hosono N, Kasahara S, Muto H, Hatano K, Ogura M, Masunari T, Tanaka M, Usuki K, Ishikawa Y, Ando K, Kondo Y, Takagi Y, Takada S, Ishikawa M, Choi I, Sano A, Nagai H.Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide.Cancer Immunol Immunother.2023: 72(8): 2865-2871.
  • 2022
    1. Ung S, Choochuen P, Khopanlert W, Maneechai K, Sangkhathat S, Terakura S, Julamanee J. Enrichment of T-cell proliferation and memory gene signatures of CD79A/CD40 costimulatory domain potentiates CD19CAR-T cell functions.Front Immunol. 2022:13:1064339.
    2. Koya Odaira, Takahiko Yasuda, Kentaro Okada, Takuya Shimooka, Yukino Kojima, Mina Noura, Shogo Tamura, Shingo Kurahashi, Eisuke Iwamoto, Masashi Sanada, Itaru Matsumura, Yasushi Miyazaki, Tetsuhito Kojima, Hitoshi Kiyoi, Shinobu Tsuzuki, Fumihiko Hayakawa. Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP-IGH fusion gene.Cancer Sci. 2022: 114(3): 781-792.
    3. Hideo Oishi, Toru Kondo, Mariko Kawamura, Kazuyuki Shimada, Masato Mutsuga, Takashi Kurokawa, Tasuku Kuwayama, Hiroaki Hiraiwa, Ryota Morimoto, Takahiro Okumura, Tetsuya Nishida, Hitoshi Kiyoi, Shinji Naganawa, Akihiko Usui, Toyoaki Murohara. Methods for confirming the safety of radiation therapy in patients with left ventricular assist device: a case of extranodal NK/T-cell lymphoma, nasal type. Int J Hematol. 2022:113:395-403.
    4. Shuichi Okamoto, Shogo Tamura, Naomi Sanda, Koya Odaira, Yuri Hayakawa, Masato Mukaide, Atsuo. VWF-Gly2752Ser, a novel non-cysteine substitution variant in the CK domain, exhibits severe secretory impairment by hampering C-terminal dimer formation. J Thromb Haemost. 2022: 20(8): 1784-1796.
    5. Yasushi Miyazaki, Toru Kiguchi, Shinya Sato, Kensuke Usuki, Ken Ishiyama, Yoshikazu Ito, Takahiro Suzuki, Jun Taguchi, Shigeru Chiba, Nobuaki Dobashi, Akihiro Tomita, Hironori Harada, Hiroshi Handa, Shigeo Horiike, Tomoya Maeda, Mitsuhiro Matsuda, Motoshi Ichikawa, Tomoko Hata, Sumihisa Honda, Satoshi Iyama, Hitoshi Suzushima, Yukiyoshi Moriuchi, Toshiro Kurokawa, Kenichi Yokota, Shigeki Ohtake, Takahiro Yamauchi, Itaru Matsumura, Hitoshi Kiyoi, Tomoki Naoe. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. Int J Hematol. 2022: 116(2): 228-238.
    6. Chikashi Yoshida, Takeshi Kondo, Tomoki Ito, Masahiro Kizaki, Kazuhiko Yamamoto, Toshihiro Miyamoto, Yasuyoshi Morita, Tetsuya Eto, Yuna Katsuoka, Naoki Takezako, Nobuhiko Uoshima, Kazunori Imad, Jun Ando, Takuya Komeno, Akio Mori, Yuichi Ishikawa, Atsushi Satake, Junichi Watanabe, Yoshiko Kawakami, Tetsuo Morita, Ikue Taneike, Masahiko Nakayama, Yinghui Duan, Belen Garbayo Guijarro, Alexander Delgado, Cynthia Llamas, Hitoshi Kiyoi. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy. Int J Hematol. 2022: 116(1): 89-101.
    7. Yukio Kobayashi, Iekuni Oh, Toshihiro Miyamoto, Won-Sik Lee, Hiroatsu Iida, Hironobu Minami, Yoshinobu Maeda, Jun Ho Jang, Sung-Soo Yoon, Su-Peng Yeh, Qui Tran, Joan Morris, Janet Franklin, Hitoshi Kiyoi. Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Asia Pac J Clin Oncol. 2022: 18(3): 311-318.
    8. Yu-Ting Dai, Fan Zhang, Hai Fang, Jian-Feng Li, Gang Lu, Lu Jiang, Bing Chen, Dong-Dong Mao, Yuan-Fang Liu, Jin Wang, Li-Jun Peng, Chong Feng, Hai-Feng Chen, Jun-Xi Mu, Qun-Ling Zhang, Hao Wang, Hany Ariffin, Tan Ah Moy, Jing-Han Wang, Yin-Jun Lou, Su-Ning Chen, Qian Wang, Hong Liu, Zhe Shan, Itaru Matsumura, Yasushi Miyazaki , Takahiko Yasuda, Li-Ping Dou, Xiao-Jing Yan, Jin-Song Yan, Allen Eng-Juh Yeoh, De-Pei Wu, Hitoshi Kiyoi, Fumihiko Hayakawa, Jie Jin, Sheng-Yue Wang, Xiao-Jian Sun, Jian-Qing Mi, Zhu Chen, Jin-Yan Huang, Sai-Juan Chen.Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases.Proc Natl Acad Sci U S A. 2022: 119(15): e2120787119.
    9. Miyao K, Kuwatsuka Y, Murata M, Nagafuji K, Teshima T, Takeuchi Y, Shiratori S, Najima Y, Uchida N, Tanaka M, Sawa M, Ota S, Fukuda T, Ozawa Y, Kako S, Kawakita T, Ara T, Tanaka J, Kanda Y, Atsuta Y, Kanda J, Terakura S; GVHD Working Group and Donor/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy. Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation.Transplant Cell Ther. 2022: 28(3): 153.e1-153.e11.
    10. Shinichi Kako, Fumihiko Hayakawa, Koichi Miyamura, Junji Tanaka, Kiyotoshi Imai, Junya Kanda, Satoko Morishima, Naoyuki Uchida, Noriko Doki, Kazuhiro Ikegame, Yukiyasu Ozawa, Satoru Takada, Noriko Usui, Shigeki Ohtake, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Yoshinobu Kanda. Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission. Transplant Cell Ther. 2022: 28(3): 161.e1-161.e10.
    11. Yoshitaka Adachi, Toshiyasu Sakai, Seitaro Terakura, Takashi Shiina, Shingo Suzuki, Hiroshi Hamana, Hiroyuki Kishi, Takehiko Sasazuki, Hisashi Arase, Ryo Hanajiri, Tatsunori Goto, Tetsuya Nishida, Makoto Murata, Hitoshi Kiyoi. Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells. Int J Hematol. 2022: 115(3): 371-381.
    12. Naomi Kawashima, Yuichi Ishikawa, Jeong Hui Kim, Yoko Ushijima, Akimi Akashi, Yohei Yamaguchi, Hikaru Hattori, Marie Nakashima, Seara Ikeno, Rika Kihara, Takahiro Nishiyama, Takanobu Morishita, Koichi Watamoto, Yukiyasu Ozawa, Kunio Kitamura, Hitoshi Kiyoi.Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells.　Nat Commun. 2022: 13(1): 1624.
    13. Takahiko Yasuda, Masashi Sanada, Masahito Kawazu, Shinya Kojima, Shinobu Tsuzuki, Hiroo Ueno, Eisuke Iwamoto, Yuka Iijima-Yamashita, Tomomi Yamada, Takashi Kanamori, Rieko Nishimura, Yachiyo Kuwatsuka, Satoru Takada, Masatsugu Tanaka, Shuichi Ota, Nobuaki Dobashi, Etsuko Yamazaki, Asao Hirose, Tohru Murayama, Masahiko Sumi, Shinya Sato, Naoyuki Tange, Yukinori Nakamura, Yuna Katsuoka, Emiko Sakaida, Toyotaka Kawamata, Hiroatsu Iida, Yuichi Shiraishi, Yasuhito Nannya, Seishi Ogawa, Masafumi Taniwaki, Norio Asou, Yoshihiro Hatta, Hitoshi Kiyoi, Itaru Matsumura, Keizo Horibe, Hiroyuki Mano, Tomoki Naoe, Yasushi Miyazaki, Fumihiko Hayakawa. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. Blood. 2022: 139(12): 1850-1862.
    14. Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Masahiko Ando, Xin Zhou, Ayana Yamagami, Takeshi Onoue, Yohei Kawaguchi, Takashi Miyata, Mariko Sugiyama, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Masahiro Morise, Keiko Wakahar, Kenji Yokota, Masashi Kato, Naoki Nishio, Chie Tanaka, Kazushi Miyata, Atsushi Ogura, Takanori Ito, Tsunaki Sawada, Tomoya Shimokata, Kaoru Niimi, Fumiharu Ohka, Masatoshi Ishigami, Momokazu Gotoh, Naozumi Hashimoto, Ryuta Saito, Hitoshi Kiyoi, Hiroaki Kajiyama, Yuichi Ando, Hideharu Hibi, Michihiko Sone, Masashi Akiyama, Yasuhiro Kodera, Hiroshi Arima.Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline.J Clin Endocrinol Metab. 2022: 107(4): e1620-e1630.
    15. Imahashi N, Terakura S, Kondo E, Kato K, Kim SW, Shinohara A, Watanabe M, Fukuda T, Uchida N, Kobayashi H, Ishikawa J, Kataoka K, Shiratori S, Ikeda T, Matsuoka KI, Yoshida S, Kondo T, Kimura T, Onizuka M, Ichinohe T, Atsuta Y, Kanda J.Impact of donor types on reduced intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.Bone Marrow Transplant. 2022: 57(2): 243-251.
    16. Akahoshi Y, Kimura SI, Tada Y, Matsukawa T, Tamaki M, Doki N, Uchida N, Tanaka M, Nakamae H, Kuriyama T, Matsuoka KI, Ikeda T, Kimura T, Fukuda T, Kanda Y, Atsuta Y, Murata M, Terakura S, Nakasone H.Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease.Blood Advances. 2022: 6(2): 574-584.
    17. Sugiura I, Doki N, Hata T, Cho R, Ito T, Suehiro Y, Tanaka M, Kako S, Matsuda M, Yokoyama H, Ishikawa Y, Taniguchi Y, Hagihara M, Ozawa Y, Ueda Y, Hirano D, Sakura T, Tsuji M, Kamae T, Fujita H, Hiramoto N, Onoda M, Fujisawa S, Hatta Y, Dobashi N, Nishiwaki S, Atsuta Y, Kobayashi Y, Hayakawa F, Ohtake S, Naoe T, Miyazaki Y.Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood Advances. 2022: 6(2): 624-636.
    18. Shimizu M, Takahashi D, Suzuki S, Shigenari A, Ito S, Miyata S, Satake M, Matsuhashi M, Kulski JK, Murata M, Azuma F, Shiina T.A novel swab storage gel is superior to dry swab DNA collection and enables long-range high resolution next generation sequencing HLA typing from buccal cell samples.HLA. 2022: 99(6): 590-606.
    19. Miyao K, Kuwatsuka Y, Murata M, Nagafuji K, Teshima T, Takeuchi Y, Shiratori S, Najima Y, Uchida N, Tanaka M, Sawa M, Ota S, Fukuda T, Ozawa Y, Kako S, Kawakita T, Ara T, Tanaka J, Kanda Y, Atsuta Y, Kanda J, Terakura S.Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation.Transplant Cell Ther. 2022:28:153. e1-153.e11.
    20. Miyazaki K, Suzuki R, Oguchi M, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Ejima Y, Katayama N, Yamaguchi M.Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.Hematol Oncol. 2022: 40(4): 667-677.
    21. Oishi H, Kondo T, Kawamura M, Shimada K, Mutsuga M, Kurokawa T, Kuwayama T, Hiraiwa H, Morimoto R, Okumura T, Nishida T, Kiyoi H, Naganawa S, Usui A, Murohara T.Methods for confirming the safety of radiation therapy in patients with left ventricular assist device: a case of extranodal NK/T-cell lymphoma, nasal type.J Artif Organs. 2022: 25(3): 274-278.
    22. Hiramoto N, Yamazaki H, Nakamura Y, Uchida N, Murata M, Kondo T, Yoshioka S, Eto T, Nishikawa A, Kimura T, Ichinohe T, Atsuta Y, Onishi Y, Suzuki R, Mori T.Total body irradiation-containing conditioning regimens without antithymocyte globulin in adults with aplastic anemia undergoing umbilical cord blood transplantation.Ann Hematol. 2022: 101(1): 165-175.
    23. Kato K, Makita S, Goto H, Kanda J, Fujii N, Shimada K, Akashi K, Izutsu K, Teshima T, Fukuda N, Sumitani T, Sumi H, Shimizu S, Kakurai Y, Yoshikawa K, Tobinai K, Usui N, Hatake K.Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma.Int J Clin Oncol. 2022: 27(1): 213-223.
    24. Ishikawa E, Nakamura M, Satou A, Shimada K, Nakamura S.Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma in the Gastrointestinal Tract in the Modern Era.Cancers (Basel). 2022: 14(2): 446.
  • 2021
    1. Shimada K,Hayashi N, Sone J, Fukami Y, Yoshida Y, Kuno S, Shimada K, Atsuta N, Nakamura T, Higuchi O, Katsuno M.Severe myasthenia gravis with anti-LRP4 antibodies and Hodgkin lymphoma.Muscle Nerve.2021:63(1).
    2. Ishikawa Y, Kiyoi H. Nishiwaki S, Sugiura I, Koyama D, Ozawa Y, Osaki M, Ishikawa Y, Kiyoi H. Machine learning-aided risk stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia.Biomark Res.2021:9(1).
    3. Kiyoi H,Suzuki A, Suzuki N, Kanematsu T, Okamoto S, Tamura S, Kikuchi R, Katsumi A, Kiyoi H, Kojima T, Matsushita T.Impact of variation in reagent combinations for one-stage clotting assay on assay discrepancy in nonsevere haemophilia A.Int J Lab Hematol.2021:43(1).
    4. Terakura S,Harada K, Fuji S, Seo S, Uchida N, Kawakita T, Yano S, Ozawa Y, Yoshioka S, Onishi Y, Noguchi Y, Onizuka M, Matsuhashi Y, Kimura T, Ichinohe T, Atsuta Y; Transplant Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation, Terakura S, Nakasone H.Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant.2021:56(2).
    5. Terakura S, Murata M.Terakura S, Kuwatsuka Y, Sugita J, Takahashi S, Ozawa Y, Ozeki K, Yoshioka S, Nakamae H, Kawakita T, Sawa M, Morishige S, Najima Y, Katsuoka Y, Sakaida E, Kouzai Y, Kimura T, Ichinohe T, Fukuda T, Atsuta Y, Murata M, Teshima T.\"Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. Int J Hematol.2021.\t
    6. Kiyoi H,Saito T, Hatta Y, Hayakawa F, Takahashi T, Hagihara M, Iida H, Minauchi K, Yamazaki E, Sugiura I, Murayama T, Sakura T, Mori N, Imai K, Yahagi Y, Atsuta Y, Saito AM, Hirakawa A, Kiyoi H, Matsumura I, Miyazaki Y; Japan Adult Leukemia Study Group.\tCombination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.Int J Hematol.2021:113(3).
    7. Nishida T, Terakura S, Murata M,Nishida T, Kobayashi T, Sawa M, Masuda S, Shibasaki Y, Goto T, Fukuhara N, Fujii N, Ikegame K, Sugita J, Ikeda T, Kuwatsuka Y, Suzuki R, Najima Y, Doki N, Kato T, Inagaki Y, Utsu Y, Aotsuka N, Masuko M, Terakura S, Onishi Y, Maeda Y, Okada M, Teshima T, Murata M.A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin.Ann Hematol.2021:100(3).
    8. Shimada K,Sakakibara A, Suzuki Y, Kato H, Yamamoto K, Sakata-Yanagimoto M, Ishikawa Y, Furukawa K, Shimada K, Kohno K, Nakamura S, Satou A, Kato S.Follicular T-cell lymphoma mimicking lymphocyte-rich classic Hodgkin lymphoma: a case report of a diagnostic pitfall.J Clin Exp Hematop.2021:Online ahead of print.
    9. Fuji S, Hakoda A, Kanda J, Murata M, Terakura S, Inamoto Y, Uchida N, Toya T, Eto T, Nakamae H, Ikegame K, Tanaka M, Kawakita T, Kondo T, Miyamoto T, Fukuda T, Ichinohe T, Kimura T, Atsuta Y, Shintani A, Morishima S.Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation.Bone Marrow Transplant.2021:56(12).
    10. Sakakibara A, Kohno K, Ishikawa E, Suzuki Y, Tsuyuki Y, Shimada S, Shimada K, Satou A, Takahara T, Ohashi A, Takahashi E, Kato S, Nakamura S, Asano N.Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.J Clin Exp Hematop.2021:61(4).
    11. Kawano T, Tsuyuki Y, Suzuki Y, Shimada K, Kato S, Takahara T, Mori M, Nakaguro M, Sakakibara A, Nakamura S, Satou A.Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells.Am J Surg Pathol.2021:45(12).
    12. Fujioka Y, Sugiyama D, Matsumura I, Minami Y, Miura M, Atsuta Y, Ohtake S, Kiyoi H, Miyazaki Y, Nishikawa H, Takahashi N.Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia.Cancers (Basel).2021:13(23).
    13. Iwama S, Kobayashi T, Yasuda Y, Okuji T, Ito M, Ando M, Zhou X, Yamagami A, Onoue T, Kawaguchi Y, Miyata T, Sugiyama M, Takagi H, Hagiwara D, Suga H, Banno R, Hase T, Morise M, Wakahara K, Yokota K, Kato M, Nishio N, Tanaka C, Miyata K, Ogura A, Ito T, Sawada T, Shimokata T, Niimi K, Ohka F, Ishigami M, Gotoh M, Hashimoto N, Saito R, Kiyoi H, Kajiyama H, Ando Y, Hibi H, Sone M, Akiyama M, Kodera Y, Arima H.Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline.J Clin Endocrinol Metab.2021:107(4):e1620-e1630.
    14. Kako S, Hayakawa F, Imai K, Tanaka J, Mizuta S, Nishiwaki S, Kanamori H, Mukae J, Ozawa Y, Kondo T, Fukuda T, Ichinohe T, Ota S, Tanaka Y, Murayama T, Kurahashi S, Sakura T, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Atsuta Y.Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.Int J Hematol.2021:114(5).
    15. Yabe T, Satake M, Odajima T, Watanabe-Okochi N, Azuma F, Kashiwase K, Matsumoto K, Orihara T, Yabe H, Kato S, Kato K, Kai S, Mori T, Morishima S, Takanashi M, Nakajima K, Murata M, Morishima Y.Combined impact of HLA-allele matching and the CD34-positive cell dose on optimal unit selection for single-unit cord blood transplantation in adults.Leuk Lymphoma.2021:62(11).
    16. Yasuda T, Sanada M, Kawazu M, Kojima S, Tsuzuki S, Ueno H, Iwamoto E, Iijima-Yamashita Y, Yamada T, Kanamori T, Nishimura R, Kuwatsuka Y, Takada S, Tanaka M, Ota S, Dobashi N, Yamazaki E, Hirose A, Murayama T, Sumi M, Sato S, Tange N, Nakamura Y, Katsuoka Y, Sakaida E, Kawamata T, Iida H, Shiraishi Y, Nannya Y, Ogawa S, Taniwaki M, Asou N, Hatta Y, Kiyoi H, Matsumura I, Horibe K, Mano H, Naoe T, Miyazaki Y, Hayakawa F.\tTwo novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.Blood.2021:139(12):1850-1862.
    17. Shimada K, Kiyoi H.Current progress, and future perspectives of research on intravascular large B-cell lymphoma.Cancer Sci.2021:112(10).
    18. Murata M, Terakura S, Wake A, Miyao K, Ikegame K, Uchida N, Kataoka K, Miyamoto T, Onizuka M, Eto T, Doki N, Ota S, Sato M, Hashii Y, Ichinohe T, Fukuda T, Atsuta Y, Okamoto S, Teshima T.Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence.Bone Marrow Transplant.2021:56(10).
    19. Oka K, Morioka H, Eguchi M, Sato Y, Tetsuka N, Iguchi M, Kanematsu T, Fukano H, Hoshino Y, Kiyoi H, Yagi T.Bursitis, Bacteremia, and Disseminated Infection of Mycobacteroides (Mycobacterium) abscessus subsp. Massiliense.Intern Med.2021:60(18).
    20. Julamanee J, Terakura S, Umemura K, Adachi Y, Miyao K, Okuno S, Takagi E, Sakai T, Koyama D, Goto T, Hanajiri R, Hudecek M, Steinberger P, Leitner J, Nishida T, Murata M, Kiyoi H.Composite CD79A/CD40 costimulatory endodomain enhances CD19CAR-T cell proliferation and survival.Mol Ther.2021:129(9).
    21. Shiratori S, Sugita J, Fuji S, Aoki J, Sawa M, Ozawa Y, Hashimoto D, Matsuoka KI, Imada K, Doki N, Ashida T, Ueda Y, Tanaka M, Sawayama Y, Ichinohe T, Terakura S, Morishima S, Atsuta Y, Fukuda T, Teshima T.\"Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors. \"Bone Marrow Transplant.2021:56(9).
    22. Shimada K.Current status of diagnosis and treatment in diffuse large B-cell lymphoma.Rinsho Ketsueki.2021:62(8).
    23. Akahoshi Y, Kimura SI, Inamoto Y, Seo S, Muranushi H, Shimizu H, Ozawa Y, Tanaka M, Uchida N, Kanda Y, Katayama Y, Shiratori S, Ota S, Matsuoka KI, Onizuka M, Fukuda T, Atsuta Y, Murata M, Terakura S, Nakasone H.Effect of Cytomegalovirus Reactivation With or Without Acute Graft-Versus-Host Disease on the Risk of Nonrelapse Mortality.Clin Infect Dis.2021:73(3).
    24. Murata M, Teshima T.Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease Using Commercial Mesenchymal Stem Cell Products.Front Immunol.2021:12.
    25. Shimada K.Current achievements and future perspectives in the research on intravascular large B-cell lymphoma.Rinsho Ketsueki.2021:62(6).
    26. Kobayashi Y, Oh I, Miyamoto T, Lee WS, Iida H, Minami H, Maeda Y, Jang JH, Yoon SS, Yeh SP, Tran Q, Morris J, Franklin J, Kiyoi H.Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Asia Pac J Clin Oncol.2021:Online ahead of print.
    27. Okuno S, Adachi Y, Terakura S, Julamanee J, Sakai T, Umemura K, Miyao K, Goto T, Murase A, Shimada K, Nishida T, Murata M, Kiyoi H.Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells.J Immuno.2021:206(12):2862-2874.
    28. Kunou S, Shimada K, Takai M, Sakamoto A, Aoki T, Hikita T, Kagaya Y, Iwamoto E, Sanada M, Shimada S, Hayakawa F, Oneyama C, Kiyoi H.Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma.Oncogene.2021:40(23).
    29. Terakura S, Kuwatsuka Y, Sugita J, Takahashi S, Ozawa Y, Ozeki K, Yoshioka S, Nakamae H, Kawakita T, Sawa M, Morishige S, Najima Y, Katsuoka Y, Sakaida E, Kouzai Y, Kimura T, Ichinohe T, Fukuda T, Atsuta Y, Murata M, Teshima T.Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.Int J Hematol.2021:113(6).
    30. Sakakibara A, Suzuki Y, Kato H, Yamamoto K, Sakata-Yanagimoto M, Ishikawa Y, Furukawa K, Shimada K, Kohno K, Nakamura S, Satou A, Kato S.Follicular T-cell lymphoma mimicking lymphocyte-rich classic Hodgkin lymphoma: a case report of a diagnostic pitfall.J Clin Exp Hematop.2021:61(2).
    31. Morichika K, Karube K, Sakihama S, Watanabe R, Kawaki M, Nishi Y, Nakachi S, Okamoto S, Takahara T, Satou A, Shimada S, Shimada K, Tsuzuki T, Fukushima T, Morishima S, Masuzaki H.The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.Am J Surg Pathol2021:45(6).
    32. Goto T, Murata M, Nishida T, Terakura S, Kamoshita S, Ishikawa Y, Ushijima Y, Adachi Y, Suzuki S, Kato K, Hirakawa A, Nishiwaki S, Nishio N, Takahashi Y, Kodera Y, Matsushita T, Kiyoi H.Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation.Stem Cells Transl Med.2021:10(4).
    33. Miyao K, Terakura S, Ozawa Y, Sawa M, Kohno A, Kasahara S, Iida H, Ino K, Kusumoto S, Kasai M, Takami A, Kurahashi S, Kajiguchi T, Morishita T, Nishida T, Murata M.Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy.Transplant Cell Ther.2021:27(4).
    34. Konuma T, Kanda J, Yamasaki S, Harada K, Shimomura Y, Terakura S, Mizuno S, Uchida N, Tanaka M, Doki N, Ozawa Y, Nakamae H, Sawa M, Matsuoka KI, Morishige S, Maruyama Y, Ikegame K, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Yanada M.\"Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. \"Transplant Cell Ther.2021:27(4).
    35. Tsuyuki Y, Ishikawa E, Kohno K, Shimada K, Ohka F, Suzuki Y, Mabuchi S, Satou A, Takahara T, Kato S, Miyagi S, Ozawa H, Kawano T, Takagi Y, Hiraga J, Wakabayashi T, Nakamura S.Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system.Neuropathology.2021:41(2).
    36. Shimada K, Yoshida K, Suzuki Y, Iriyama C, Inoue Y, Sanada M, Kataoka K, Yuge M, Takagi Y, Kusumoto S, Masaki Y, Ito T, Inagaki Y, Okamoto A, Kuwatsuka Y, Nakatochi M, Shimada S, Miyoshi H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shiozawa Y, Nannya Y, Okabe A, Kohno K, Atsuta Y, Ohshima K, Nakamura S, Ogawa S, Tomita A, Kiyoi H.Frequent Genetic Alterations in Immune Checkpoint-Related Genes in Intravascular Large B-Cell Lymphoma.Blood.2021:137(11).
    37. Nishiwaki S, Sugiura I, Koyama D, Ozawa Y, Osaki M, Ishikawa Y, Kiyoi H.Machine learning-aided risk stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia. Biomark Res.Biomark Res.2021:9(1).
    38. Kanematsu T, Suzuki N, Tamura S, Suzuki A, Ishikawa Y, Katsumi A, Kiyoi H, Saito H, Kunishima S, Kojima T, Matsushita T. Myh9 R702C is associated with erythroid abnormality with splenomegaly in mice.Nagoya J Med Sci.2021:83(1).
  • 2020
    1. Kiyoi H, Morris JD, Oh I, Maeda Y, Minami H, Miyamoto T, Sakura T, Iida H, Tuglus CA, Chen Y, Dos Santos C, Kalabus J, Anderson A, Hata T, Nakashima Y, Kobayashi Y.Phase 1b/2 study of blinatumomab in Japanese adults with relapsed refractory acute lymphoblastic leukemia.Cancer Sci.2020:111(4).
    2. Kiyoi H, Yamaguchi H, Maeda Y, Yamauchi T.JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML).Int J Hematol.2020:111(5)
    3. Yamamoto F, Suzuki S, Mizutani A, Shigenari A, Ito S, Kametani Y, Kato S, Fernandez-Viña M, Murata M, Morishima S, Morishima Y, Tanaka M, Kulski JK, Bahram S, Shiina T. Capturing Differential Allele-Level Expression and Genotypes of All Classical HLA Loci and Haplotypes by a New Capture RNA-Seq Method. Front Immunol.2020:11.
    4. Takeshita A, Asou N, Atsuta Y, Furumaki H, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Minamiguchi H, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y, Group TJALS.Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature.Cancers (Basel).2020:12(6).
    5. Fujita H, Ishikawa Y, Yokoyama Y.JSH practical guidelines for hematological malignancies.2018:I. Leukemia-2. Acute promyelocytic leukemia (APL).Int J Hematol.2020:111(6).
    6. Yokoyama H, Takenaka K, Nishida T, Seo S, Shinohara A, Uchida N, Tanaka M, Takahashi S, Onizuka M, Kozai Y, Yasuhiro S, Ozawa Y, Katsuoka Y, Doki N, Sawa M, Kimura T, Kanda J, Fukuda T, Atsuta Y, Nakasone H; Japan Society for Hematopoietic Cell Transplantation Transplantation-Related Complication Working Group.Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type \" Biol Blood Marrow Transplant. \".2020:26(7).
    7. Terakura S, Nishida T, Sawa M, Kato T, Miyao K, Ozawa Y, Goto T, Kohno A, Ozeki K, Onishi Y, Fukuhara N, Fujii N, Yokoyama H, Kasai M, Iida H, Kanemura N, Endo T, Ago H, Onizuka M, Iyama S, Nawa Y, Nakamae M, Nagata Y, Kurahashi S, Tomiya Y, Yanagisawa A, Suzuki R, Kuwatsuka Y, Atsuta Y, Miyamura K, Murata M.Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome.Bone Marrow Transplant.2020:55(7).
    8. Kawashima N, Ishikawa Y, Atsuta Y, Sawa M, Ozawa Y, Hayashi M, Kohno A, Tomita A, Maeda T, Sakaida E, Usuki K, Hagihara M, Kanamori H, Matsuoka H, Kobayashi M, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H; Japan Adult Leukemia Study Group (JALSG).Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study.Cancer Sci.2020:111(7).
    9. Suzuki Y, Kohno K, Matsue K, Sakakibara A, Ishikawa E, Shimada S, Shimada K, Mabuchi S, Takahara T, Kato S, Nakamura S, Satou A.PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.Cancer Med.2020:9(13).
    10. Sakai T, Terakura S, Miyao K, Okuno S, Adachi Y, Umemura K, Julamanee J, Watanabe K, Hamana H, Kishi H, Leitner J, Steinberger P, Nishida T, Murata M, Kiyoi H.\tArtificial T Cell Adaptor Molecule-Transduced TCR-T Cells Demonstrated Improved Proliferation Only When Transduced in a Higher Intensity.Mol Ther Oncolytics.2020:18.
    11. Murata M, Suzuki R, Nishida T, Shirane S, Shimazu Y, Minami Y, Mori T, Doki N, Kanda Y, Uchida N, Tanaka M, Ishikawa J, Togitani K, Fukuda T, Ichinohe T, Atsuta Y, Nagamura-Inoue T, Kiyoi H.Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.Intern Med.2020:59(16).
    12. Tange N, Hayakawa F, Yasuda T, Odaira K, Yamamoto H, Hirano D, Sakai T, Terakura S, Tsuzuki S, Kiyoi H. Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells.Biomed Pharmacother.2020
    13. Yamashita D, Shimada K, Kohno K, Kogure Y, Kataoka K, Takahara T, Suzuki Y, Satou A, Sakakibara A, Nakamura S, Asano N, Kato S.PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma:A clinicopathological study of 50 cases.Pathol Int.2020:70(8).
    14. Yasuda T, Sanada M, Nishijima D, Kanamori T, Iijima Y, Hattori H, Saito A, Miyoshi H, Ishikawa Y, Asou N, Usuki K, Hirabayashi S, Kato M, Ri M, Handa H, Ishida T, Shibayama H, Abe M, Iriyama C, Karube K, Nishikori M, Ohshima K, Kataoka K, Yoshida K, Shiraishi Y, Goto H, Adachi S, Kobayashi R, Kiyoi H, Miyazaki Y, Ogawa S, Kurahashi H, Yokoyama H, Manabe A, Iida S, Tomita A, Horibe K.Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study.Cancer Sci.2020:111(9).
    15. Kimura SI, Fujita H, Handa H, Hiramoto N, Hosono N, Minamiguchi H, Takahashi T, Kato H, Ono T, Kanda Y, Kiyoi H, Matsumura I, Miyazaki Y; Japan Adult Leukemia Study Group (JALSG).Real-world management of infection during chemotherapy for acute leukemia in Japan: from the results of a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group.Int J Hematol.2020:112(3).
    16. Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, Uchida N, Fukushima K, Ashida T, Matsuoka KI, Kanda J, Ichinohe T, Atsuta Y, Murata M, Aoki J.Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.2020:26(9).
    17. Kazama S, Hiraiwa H, Kimura Y, Ozaki R, Shibata N, Arao Y, Oishi H, Kato H, Kuwayama T, Yamaguchi S, Kondo T, Furusawa K, Morimoto R, Okumura T, Bando YK, Sato T, Shimada K, Kiyoi H, Nakamura G, Yasuda Y, Kasugai D, Ogawa H, Higashi M, Yamamoto T, Jingushi N, Ozaki M, Numaguchi A, Goto Y, Matsuda N, Murohara T.A case of reexpansion pulmonary edema and acute pulmonary thromboembolism associated with diffuse large B-cell lymphoma treated with venovenous extracorporeal membrane oxygenation.J Cardiol Cases.2020:23(1).
    18. Nishiwaki S, Kim JH, Ito M, Maeda M, Okuno Y, Koyama D, Ozawa Y, Gunji M, Osaki M, Kitamura K, Ushijima Y, Ishikawa Y, Miyamura K, Sugiura I, Kiyoi H.Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular Features. Front Oncol. 2020.
    19. Izutsu K, Kato K, Kiyoi H, Yamamoto G, Shimada K, Akashi K.Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma.Int J Hematol.2020:112(4).
    20. Kagami Y, Yamamoto K, Shibata T, Tobinai K, Imaizumi Y, Uchida T, Shimada K, Minauchi K, Fukuhara N, Kobayashi H, Yamauchi N, Tsujimura H, Hangaishi A, Tominaga R, Suehiro Y, Yoshida S, Inoue Y, Suzuki S, Tokuhira M, Kusumoto S, Kuroda J, Yakushijin Y, Takamatsu Y, Kubota Y, Nosaka K, Morishima S, Nakamura S, Ogura M, Maruyama D, Hotta T, Morishima Y, Tsukasaki K, Nagai H.R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.Cancer Sci.2020:110(10).
    21. Sato T, Kawashima N, Ito M, Atsuta Y, Kagaya Y, Seto A, Morishita T, Fukushima N, Ozawa Y, Miyamura K.Day 0 bone marrow pathology of allogeneic hematopoietic stem cell transplantation is a novel prognostic factor in myeloid malignancies.Blood Cell Therapy.2020:3(4).
    22. Imahashi N, Terakura S, Kondo E, Kako S, Uchida N, Kobayashi H, Inamoto Y, Sakai H, Tanaka M, Ishikawa J, Kozai Y, Matsuoka KI, Kimura T, Fukuda T, Atsuta Y, Kanda J; Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation.Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies.Bone Marrow Transplant.2020:55(11).
    23. Ito A, Kim SW, Matsuoka KI, Kawakita T, Tanaka T, Inamoto Y, Toubai T, Fujiwara SI, Fukaya M, Kondo T, Sugita J, Nara M, Katsuoka Y, Imai Y, Nakazawa H, Kawashima I, Sakai R, Ishii A, Onizuka M, Takemura T, Terakura S, Iida H, Nakamae M, Higuchi K, Tamura S, Yoshioka S, Togitani K, Kawano N, Suzuki R, Suzumiya J, Izutsu K, Teshima T, Fukuda T.Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study. \"Int J Hematol.2020:112(5).
    24. Miyao K, Terakura S, Kimura F, Konuma T, Miyamura K, Yanada M, Kako S, Morhishima S, Uchida N, Toya T, Ozawa Y, Fukuda T, Tanaka M, Sawa M, Takada S, Yoshida S, Kimura T, Ichinohe T, Atsuta Y, Kanda J; Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation.Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia. Biol Blood Marrow Transplant.2020:26(11).
    25. Miyagi S, Ishikawa E, Nakamura M, Shimada K, Yamamura T, Furukawa K, Tanaka T, Mabuchi S, Tsuyuki Y, Kohno K, Sakakibara A, Satou A, Kato S, Fujishiro M, Nakamura S.Reappraisal of Primary Epstein-Barr Virus (EBV)-positive Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract: Comparative Analysis Among Immunosuppressed and Nonimmunosuppressed Stage I and II-IV Patients.Am J Surg Pathol.2020:44(9).
    26. Shimada K, Yoshida K, Suzuki Y, Iriyama C, Inoue Y, Sanada M, Kataoka K, Yuge M, Takagi Y, Kusumoto S, Masaki Y, Ito T, Inagaki Y, Okamoto A, Kuwatsuka Y, Nakatochi M, Shimada S, Miyoshi H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shiozawa Y, Nannya Y, Okabe A, Kohno K, Atsuta Y, Ohshima K, Nakamura S, Ogawa S, Tomita A, Kiyoi H.Frequent Genetic Alterations in Immune Checkpoint-Related Genes in Intravascular Large B-Cell Lymphoma.Blood.2020:Online ahead of print.
    27. Goto T, Murata M, Nishida T, Terakura S, Kamoshita S, Ishikawa Y, Ushijima Y, Adachi Y, Suzuki S, Kato K, Hirakawa A, Nishiwaki S, Nishio N, Takahashi Y, Kodera Y, Matsushita T, Kiyoi H.Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation.Stem Cells Transl Med.2020:Online ahead of print.
    28. Minamiguchi H, Fujita H, Atsuta Y, Asou N, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Uchino Y, Tomita A, Tamaki S, Hagihara M, Fujimaki K, Yanada M, Maeda Y, Iwanaga M, Usui N, Kobayashi Y, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Naoe T, Takeshita A; Japan Adult Leukemia Study Group. Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia.Ann Hematol.2020:99(12).
    29. Akahoshi Y, Kimura SI, Inamoto Y, Seo S, Muranushi H, Shimizu H, Ozawa Y, Tanaka M, Uchida N, Kanda Y, Katayama Y, Shiratori S, Ota S, Matsuoka KI, Onizuka M, Fukuda T, Atsuta Y, Murata M, Terakura S, Nakasone H.Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality.Clin Infect Dis.2020:Online ahead of print.
    30. Terakura S, Konuma T, Tanaka M, Ozawa Y, Onizuka M, Nanno S, Onishi Y, Aotsuka N, Kondo T, Kawakita T, Kato J, Kobayashi T, Nishida T, Yamaguchi T, Kuwatsuka Y, Takahashi S.\"Randomised controlled trial of conditioning regimen for cord blood transplantation for adult myeloid malignancies comparing high-dose cytarabine/cyclophosphamide/total body irradiation with versus without G-CSF priming: G-CONCORD study protocol. \"BMJ Open.2020:10(12).
    31. Matsuda S, Suzuki R, Takahashi T, Suehiro Y, Tomita N, Izutsu K, Fukuhara N, Imaizumi Y, Shimada K, Nakazato T, Yoshida I, Miyazaki K, Yamaguchi M, Suzumiya J.Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.Int J Hematol.2020:112(6).
    32. Tsuyuki Y, Ishikawa E, Kohno K, Shimada K, Ohka F, Suzuki Y, Mabuchi S, Satou A, Takahara T, Kato S, Miyagi S, Ozawa H, Kawano T, Takagi Y, Hiraga J, Wakabayashi T, Nakamura S.Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system.Neuropathology.2020 Dec:Online ahead of print.
  • 2019
    1. Yamamoto H, Hayakawa F, Yasuda T, Odaira K, Minamikawa Y, Tange N, Hirano D, Kojima Y, Morishita T, Tsuzuki S, Naoe T, Kiyoi H. ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities. FEBS Lett. 2019:593:2151-2161.
    2. Okamoto S, Suzuki N, Suzuki A, Suzuki S, Tamura S, Suzuki M, Takahashi N, Kojima T, Kanematsu T, Kojima T, Kiyoi H, Ishiguro N, Matsushita T. Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors. TH Open. 2019:3:e364-366.
    3. Satou A, Tabata T, Miyoshi H, Kohno K, Suzuki Y, Yamashita D, Shimada K, Kawasaki T, Sato Y, Yoshino T, Ohshima K, Takahara T, Tsuzuki T, Nakamura S. Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases. Mod Pathol. 2019:32:1135-1146.
    4. Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronné L, Kogure Y, Sato Y, Nishida K, Gion Y, Shiraishi Y, Tanaka H, Chiba K, Watatani Y, Kakiuchi N, Shiozawa Y, Yoshizato T, Yoshida K, Makishima H, Sanada M, Onozawa M, Teshima T, Yoshiki Y, Ishida T, Suzuki K, Shimada K, Tomita A, Kato M, Ota Y, Izutsu K, Demachi-Okamura A, Akatsuka Y, Miyano S, Yoshino T, Gaulard P, Hermine O, Takeuchi K, Ohshima K, Ogawa S.Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 2019:33:1687-1699.
    5. Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P,Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH MS, Wheeler AP,Young G, Zupancic-Salek S, Oldenburg J. Subcutaneous concizumab prophylaxis inhemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results.Blood.2019:134:1973-1982.
    6. Suzuki A, Suzuki N, Kanematsu T, Shinohara S, Arai N, Kikuchi R, Matsushita T.Performance evaluation of Revohem(™) FVIII chromogenic and Revohem(™) FIX chromogenic in the CS-5100 autoanalyser.Int J Lab Hematol. 2019:41:664-670.
    7. Fukutake K, Taki M, Matsushita T, Sakai M, Takata A, Yamaguchi H, Karumori T.Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B.Haemophilia. 2019:25:e247-e256.
    8. Hirose S, Hioki Y, Miyashita H, Hirade N, Yoshitake J, Shibata T, Kikuchi R, Matsushita T, Chikazawa M, Itakura M, Zhang M, Nagata K, Uchida K.Apolipoprotein E binds to and reduces serum levels of DNA-mimicking, pyrrolated proteins.J Biol Chem. 2019:294:11035-11045.
    9. Odaira K, Tamura S, Suzuki N, Kakihara M, Hattori Y, Tokoro M, Suzuki S, Takagi A, Katsumi A, Hayakawa F, Okamoto S, Suzuki A, Kanematsu T, Matsushita T, Kojima T.Apparent synonymous mutation F9 c.87A>G causes secretion failure by in-frame mutation with aberrant splicing.Thromb Res. 2019:179:95-103.
    10. Davis J, Yan S, Matsushita T, Alberio L, Bassett P, Santagostino E.Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP. J Med Econ. 2019;22:1014-1021.
    11. Nagao A, Suzuki N, Takedani H, Yamasaki N, Chikasawa Y, Sawada A, Kanematsu T, Nojima M, Higasa S, Amano K, Fukutake K, Fujii T, Matsushita T, Suzuki T.Ischaemic events are rare, and the prevalence of hypertension is not high in Japanese adults with haemophilia: First multicentre study in Asia. Haemophilia. 2019:25:e223-e230.
    12. Tamura S, Hashimoto E, Suzuki N, Kakihara M, Odaira K, Hattori Y, Tokoro M, Suzuki S, Takagi A, Katsumi A, Hayakawa F, Suzuki A, Okamoto S, Kanematsu T, Matsushita T, Kojima T.Molecular basis of SERPINC1 mutations in Japanese patients with antithrombin deficiency. Thromb Res. 2019:178:159-170.
    13. Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, Okuno T, Murakami N, Yoshida K, Sawada A, Inoue M, Kawa K, Seto M, Ohshima K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Narita Y, Yoshida M, Goshima F, Kawada JI, Nishida T, Kiyoi H, Kato S, Nakamura S, Morishima S, Yoshikawa T, Fujiwara S, Shimizu N, Isobe Y, Noguchi M, Kikuta A, Iwatsuki K, Takahashi Y, Kojima S, Ogawa S, Kimura H.Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019:4:404-413.
    14. Hirano D, Hayakawa F, Yasuda T, Tange N, Yamamoto H, Kojima Y, Morishita T, Imoto N, Tsuzuki S, Mano H, Naoe T, Kiyoi H.Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity.Oncogene. 2019:38:2263-2274.
    15. Sakamoto A, Kunou S, Shimada K, Tsunoda M, Aoki T, Iriyama C, Tomita A, Nakamura S, Hayakawa F, Kiyoi H.Pyruvate secreted from patient-derived cancer-associated fibroblasts supports survival of primary lymphoma cells.Cancer Sci. 2019:110:269-278.
    16. Koyama D, Murata M, Hanajiri R, Akashi T, Okuno S, Kamoshita S, Julamanee J, Takagi E, Miyao K, Sakemura R, Goto T, Terakura S, Nishida T, Kiyoi H.Quantitative Assessment of T Cell Clonotypes in Human Acute Graft-versus-Host Disease Tissues.Biol Blood Marrow Transplant. 2019:25:417-423.
    17. Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kitamura K, Sakaida E, Takeshita A, Suzushima H, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H.Japan Adult Leukemia Study Group (JALSG).Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.Ann Hematol. 2019:98:83-91.
    18. Takeshita A, Asou N, Atsuta Y, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Furumaki H, Obata Y, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y; and the Japanese Adult Leukemia Study Group.Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.Leukemia. 2019:33:358-370.
    19. Murata M, Takenaka K, Uchida N, Ozawa Y, Ohashi K, Kim SW, Ikegame K, Kanda Y, Kobayashi H, Ishikawa J, Ago H, Hirokawa M, Fukuda T, Atsuta Y, Kondo T.Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups.Biol Blood Marrow Transplant. 2019:25:1536-1543
    20. Wakamatsu M, Terakura S, Ohashi K, Fukuda T, Ozawa Y, Kanamori H, Sawa M, Uchida N, Ota S, Matsushita A, Kanda Y, Nakamae H, Ichinohe T, Kato K, Murata M, Atsuta Y, Teshima T; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.Blood Adv. 2019:3:105-115.
    21. Takamatsu H, Yamashita T, Kurahashi S, Saitoh T, Kondo T, Maeda T, Nakazawa H, Murata M, Narita T, Kuroda J, Hashimoto H, Kawamura K, Miyamoto T, Honda S, Ichinohe T, Atsuta Y, Sunami K.Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.Biol Blood Marrow Transplant. 2019:25:474-479.
    22. Kato M, Kurata M, Kanda J, Kato K, Tomizawa D, Kudo K, Yoshida N, Watanabe K, Shimada H, Inagaki J, Koh K, Goto H, Kato K, Cho Y, Yuza Y, Ogawa A, Okada K, Inoue M, Hashii Y, Teshima T, Murata M, Atsuta Y.Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia.Bone Marrow Transplant. 2019:54:68-75.
    23. Samuelson Bannow B, Recht M, Négrier C, Hermans C, Berntorp E, Eichler H, Mancuso ME, Klamroth R, O'Hara J, Santagostino E, Matsushita T, Kessler C.Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.Blood Rev. 2019:35:43-50.
    24. Fukutake K, Taki M, Matsushita T, Nogami K, Shima M, Yoshioka A, Takamatsu J, Uchikawa H, Takagi H, Arai M, Engl W, Shirahata A.Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan.Int J Hematol. 2019:109:336-345.
    25. Suzuki A, Suzuki N, Kanematsu T, Shinohara S, Arai N, Kikuchi R, Matsushita T.Clot waveform analysis in Clauss fibrinogen assay contributes to classification of fibrinogen disorders.Thromb Res. 2019:174:98-103.
    26. Taki M, Fukutake K, Matsushita T, Nogami K, Shima M, Yoshioka A, Takamatsu J, Arai M, Takagi H, Uchikawa H, Engl W, Shirahata A.Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.Int J Hematol. 2019:109:70-78.
    27. Maeda Y, Ugai T, Kondo E, Ikegame K, Murata M, Uchida N, Miyamoto T, Takahashi S, Ohashi K, Nakamae H, Fukuda T, Onizuka M, Eto T, Ota S, Hirokawa M, Ichinohe T, Atsuta Y, Kanda Y, Kanda J.HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome.Haematologica. 2019:104:1055-1061
  • 2018
    1. Hattori H, Ishikawa Y, Kawashima N, Akashi A, Yamaguchi Y, Harada Y, Hirano D, Adachi Y, Miyao K, Ushijima Y, Terakura S, Nishida T, Matsushita T, Kiyoi H. Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia. PLoS One. 2018:13:e0204850
    2. Shimada K, Hayakawa F, Kiyoi H. Biology and management of primary effusion lymphoma. Blood. 2018:132:1879-1888.
    3. Seto A, Atsuta Y, Kawashima N, Ozawa Y, Miyamura K, Kiyoi H. Impact of hospital length of stay on the risk of readmission and overall survival after allogeneic stem cell transplantation. Int J Hematol. 2018:108:290-297
    4. Ueda N, Uemura Y, Zhang R, Kitayama S, Iriguchi S, Kawai Y, Yasui Y, Tatsumi M, Ueda T, Liu TY, Mizoro Y, Okada C, Watanabe A, Nakanishi M, Senju S, Nishimura Y, Kuzushima K, Kiyoi H, Naoe T, Kaneko S. Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response. Stem Cell Reports. 2018:10:1935-1946.
    5. Goto T, Murata M, Terakura S, Nishida T, Adachi Y, Ushijima Y, Shimada K, Ishikawa Y, Hayakawa F, Nishio N, Nishiwaki S, Hirakawa A, Kato K, Takahashi Y, Kiyoi H. Phase I study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells: A clinical study protocol. Medicine (Baltimore).2018:97:e0449.
    6. Miyao K, Terakura S, Okuno S, Julamanee J, Watanabe K, Hamana H, Kishi H, Sakemura R, Koyama D, Goto T, Nishida T, Murata M, Kiyoi H. Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs. Cancer Immunol Res. 2018:6:733-744.
    7. Nishiyama T, Ishikawa Y, Kawashima N, Akashi A, Adachi Y, Hattori H, Ushijima Y, Kiyoi H. Mutation analysis of therapy-related myeloid neoplasms. Cancer Genetics. 2018;222-223:38-45.
    8. Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Onizuka M, Takeshita A, Ishida F, Suzushima H, Ishizawa K, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group JALSG. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leuk Res. 2018;66:20-27.
    9. Yamaura T, Nakatani T, Uda K, Ogura H, Shin W, Kurokawa N, Saito K, Fujikawa N, Date T, Takasaki M, Terada D, Hirai A, Akashi A, Chen F, Adachi Y, Ishikawa Y, Hayakawa F, Hagiwara S, Naoe T, Kiyoi H. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood. 2018;131:426-438.
    10. Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S, Adachi S, Kiyoi H. Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. Int J Hematol.2018;107:201-210.
  • 2017
    1. Adachi Y, Ishikawa Y, Kiyoi H. Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia. Oncotarget 2017;8:78452-78465.
    2. Kojima Y, Hayakawa F, Morishita T, Sugimoto K, Minamikawa Y, Iwase M, Yamamoto H, Hirano D, Imoto N, Shimada K, Okada S, Kiyoi H. YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma. Pharmacol Res. 2017;120:242-251.
    3. Terakura S, Kuwatsuka Y, Yamasaki S, Wake A, Kanda J, Inamoto Y, Mizuta S, Yamaguchi T, Uchida N, Kouzai Y, Aotsuka N, Ogawa H, Kanamori H, Nishiwaki K, Miyakoshi S, Onizuka M, Amano I, Fukuda T, Ichinohe T, Atsuta Y, Murata M, Teshima T. GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Bone Marrow Transplant. 2017;52:1261-1267
    4. Murata M, Maeda Y, Masuko M, Onishi Y, Endo T, Terakura S, Ishikawa Y, Iriyama C, Ushijima Y, Goto T, Fujii N, Tanimoto M, Kobayashi H, Shibasaki Y, Fukuhara N, Inamoto Y, Suzuki R, Kodera Y, Matsushita T, Kiyoi H, Naoe T, Nishida T. Phase II study of intrabone single unit cord blood transplantation for hematological malignancies. Cancer Sci. 2017;108:1634-1639
    5. Kawashima N, Terakura S, Nishiwaki S, Koyama D, Ozawa Y, Ito M, Miyamura K. Increase of bone marrow macrophages and CD8(+) T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation. Bone Marrow Transplant. 2017;52:1164-1170
    6. Terakura S, Wake A, Inamoto Y, Murata M, Sakai R, Yamaguchi T, Takahashi S, Uchida N, Onishi Y, Ohashi K, Ozawa Y, Kanamori H, Yamaguchi H, Fukuda T, Ichinohe T, Takanashi M, Atsuta Y, Teshima T. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. Bone Marrow Transplant. 2017;52:423-430.
    7. Murata M, Ikegame K, Morishita Y, Ogawa H, Kaida K, Nakamae H, Ikeda T, Nishida T, Inoue M, Eto T, Kubo K, Sakura T, Mori T, Uchida N, Ashida T, Matsuhashi Y, Miyazaki Y, Ichinohe T, Atsuta Y, Teshima T. Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GVHD: an analysis of the JSHCT. Bone Marrow Transplant. Bone Marrow Transplant. 2017;52:252-257.
    8. Aoki T, Shimada K, Sakamoto A, Sugimoto K, Morishita T, Kojima Y, Shimada S, Kato S, Iriyama C, Kuno S, Harada Y, Tomita A, Hayakawa F, Kiyoi H. Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism. Oncotarget. 2017;8:13085-13098.
    9. Suzuki N, Hirakawa A, Kishimoto M, Kanematsu T, Ogawa M, Kiyoi H, Matsushita T. Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study. Haemophilia. 2017;23:215-221.
    10. Nishiwaki S, Sugiura I, Miyata Y, Saito S, Sawa M, Nishida T, Miyamura K, Kuwatsuka Y, Kohno A, Yuge M, Kasai M, Iida H, Kurahashi S, Osaki M, Goto T, Terakura S, Murata M, Nishikawa H, Kiyoi H. Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: A study protocol for a multicenter exploratory prospective study (Auto-Ph17 study). Medicine (Baltimore). 2017;96:e9568.
    11. Koyama D, Murata M, Hanajiri R, Okuno S, Kamoshita S, Julamanee J, Takagi E, Hirano D, Miyao K, Sakemura R, Goto T, Hayakawa F, Seto A, Ozawa Y, Miyamura K, Terakura S, Nishida T, Kiyoi H. High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype. PLoS One. 2017;12:e0185213.
    12. Shirahata-Adachi M, Iriyama C, Tomita A, Suzuki Y, Shimada K, Kiyoi H. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome. Leuk Res. 2017; 63: 90-97.
  • 2016
    1. Goto T, Nishida T, Takagi E, Miyao K, Koyama D, Sakemura R, Hanajiri R, Watanabe K, Imahashi N, Terakura S, Murata M, Kiyoi H. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy. J Immunother, 2016 Oct;39(8):306-15.
    2. Suzuki N, Hirakawa A, Kishimoto M, Kanematsu T, Ogawa M, Kiyoi H, Matsushita T. Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study. Haemophilia, 2016.Oct.
    3. Takagi Y, Shimada K, Shimada S, Sakamoto A, Naoe T, Nakamura S, Hayakawa F, Tomita A, Kiyoi H. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. Cancer Sci, 2016 Sep;107(9):1270-80.
    4. Suzuki Y, Tomita A, Nakamura F, Iriyama C, Shirahata-Adachi M, Shimada K, Akashi A, Ishikawa Y, Kaneda N, Kiyoi H. Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes. Cancer Sci, 2016 Sep;107(9):1329-37.
    5. Niwa Y, Minami Y, Abe A, Hayakawa F, Yamada K, Naoe T. Wnt signaling is associated with cell survival in the interaction between acute myeloid leukemia cells and stromal cells. Leuke lymphoma,2016 Sep;57(9):2192-4.
    6. Morishita T, Hayakawa F, Sugimoto K, Iwase M, Yamamoto H, Hirano D, Kojima Y, Imoto N, Naoe T, Kiyoi H. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib. Oncotarget, 2016.Aug.
    7. Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, Koyama D, Goto T, Hanajiri R, Nishida T, Murata M, Kiyoi H. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. Cancer Immunol Res, 2016 Aug;4(8):658-68.
    8. Fukushima N, Minami Y, Kakiuchi S, Kuwatsuka Y, Hayakawa F, Jamieson C, Kiyoi H, Naoe T. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci, 2016.Jul.
    9. Shimada K, Shimada S, Sugimoto K, Nakatochi M, Suguro M, Hirakawa A, Hocking TD, Takeuchi I, Tokunaga T, Takagi Y, Sakamoto A, Aoki T, Naoe T, Nakamura S, Hayakawa F, Seto M, Tomita A, Kiyoi H. Development and analysis of patient derived xenograft mouse models in intravascular large B-cell lymphoma. Leukemia, 2016 Jul;30(7):1568-79.
    10. Inagaki Y, Hayakawa F, Hirano D, Kojima Y, Morishita T, Yasuda T, Naoe T, Kiyoi H. PAX5 tyrosine phosphorylation by SYK co-operatively functions with its serine phosphorylation to cancel the PAX5-dependent repression of BLIMP1: A mechanism for antigen-triggered plasma cell differentiation. Biochem Biophys Res Commun, 2016 Jun;475(2):176-81.
    11. Chen F, Ishikawa Y, Akashi A, Naoe T, Kiyoi H. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget, 2016 Jun.
    12. Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet, 2016 May;48(5):569-74.
    13. Imoto N, Hayakawa F, Kurahashi S, Morishita T, Kojima Y, Yasuda T, Sugimoto K, Tsuzuki S, Naoe T, Kiyoi H. BLNK is a selective target of repression by PAX5-PML in the differentiation block that leads to the development of acute lymphoblastic leukemia. J Biol Chem, 2016 Feb;291(9):4723-31.
    14. Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, Najima Y,
    15. Fukuda T, Uchida N, Takahashi S, Nagamura-Inoue T, Morishima Y, Miyamura K; Japan Society for Hematopoietic Cell Transplantation. Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit
    16. Cord Blood Transplantation in Adults with Acute Leukemia. Biol Blood Marrow Transplant, 2016 Feb;22(2):330-8.
    17. Kishimoto M, Suzuki N, Murata M, Ogawa M, Kanematsu T, Takagi A, Kiyoi H, Kojima T, Matsushita T. The first case of antithrombin-resistant prothrombin Belgrade mutation in Japanese. Ann Hematol, 2016 Feb;95(3):541-2.
    18. Kanematsu T, Suzuki N, Yoshida T, Kishimoto M, Aoki T, Ogawa M, Kagami Y, Kiyoi H, Matsushita T, Kunishima S. A case of MYH9 disorders caused by a novel mutation (p.K74E). Ann Hematol, 2016 Jan;95(1):161-3.
    19. Miyao K, Sawa M, Kuwatsuka Y, Ozawa Y, Kato T, Kohno A, Sao H, Nishida T, Iida H, Naito K, Tsurumi H, Taji H, Mizuta S, Kusumoto S, Nakase K, Morishita Y, Kawashima N, Miyamura K, Murata M. Influence of melphalan plus fludarabine- conditioning regimen in elderly patients aged ≥ 55 years with hematological malignancies.\tBone Marrow Transplant, 2016 Jan;51(1):157-60.
  • 2015
    1. Aoki T, Shimada K, Suzuki R, Izutsu K, Tomita A, Maeda Y, Takizawa J, Mitani K, Igarashi T, Sakai K, Miyazaki K, Mihara K, Ohmachi K, Nakamura N, Takasaki H, Kiyoi H, Nakamura S, Kinoshita T, Ogura M. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J, 2015 Dec;5:e372.
    2. Hanajiri R, Murata M, Sugimoto K, Murase M, Sakemura R, Goto T, Watanabe K, Imahashi N, Terakura S, Ohashi H, Akatsuka Y, Kurahashi S, Miyamura K, Kiyoi H, Nishida T, Naoe T. Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection. Bone Marrow Transplant, 2015 Sep;50(9):1187-94.
    3. Suzuki N, Takedani H, Hirakawa A, Ushijima Y, Matsushita T. The features of clearance in recombinant factor IX (BeneFIX(®)). Haemophilia. 2015 Sep;21(5):702-7.
    4. Sugimoto K, Hayakawa F, Shimada S, Morishita T, Shimada K, Katakai T, Tomita A, Kiyoi H, Naoe T. Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Sci Rep, 2015 Aug;5:13054.
    5. Imahashi N, Ohashi H, Terakura S, Miyao K, Sakemura R, Kato T, Sawa M, Yokohata E, Kurahashi S, Ozawa Y, Nishida T, Kiyoi H, Watamoto K, Kohno A, Kasai M, Kato C, Iida H, Naoe T, Miyamura K, Murata M; for the Nagoya Blood and Marrow Transplantation Group. Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse. Ann Hematol, 2015 Jul;94(7):1139-48.
    6. Imahashi N, Nishida T, Goto T, Terakura S, Watanabe K, Hanajiri R, Sakemura R, Imai M, Kiyoi H, Naoe T, Murata M. Simple and Efficient Generation of Virus-specific T Cells for Adoptive Therapy Using Anti-4-1BB Antibody. J Immunother, 2015 Feb-Mar;38(2):62-70.
    7. Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, Shimada K, Tomita A, Kiyoi H, Nishida T, Naoe T, Murata M. Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 ζ Chimeric Antigen Receptor-Modified Effector CD8+ T Cells. J Immunol, 2015 Feb;194(3): 911-20.
  • 2014
    1. Aoki T, Izutsu K, Suzuki R, Nakaseko C, Arima H, Shimada K, Tomita A, Sasaki M, Takizawa J, Mitani K, Igarashi T, Maeda Y, Fukuhara N, Ishida F, Niitsu N, Ohmachi K, Takasaki H, Nakamura N, Kinoshita T, Nakamura S, Ogura M. Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. Haematologica, 2014 Dec;99(12):1817-25.
    2. Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, Miyatake J, Handa H, Ueda Y, Aoyama Y, Takada S, Tanaka Y, Usui N, Miyawaki S, Suenobu S, Horibe K, Kiyoi H, Ohnishi K, Miyazaki Y, Ohtake S, Kobayashi Y, Matsuo K, Naoe T; Japan Adult Leukemia Study Group (JALSG). Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J, 2014 Oct;4:e252.
    3. Kishimoto M, Matsuda T, Yanase S, Katsumi A, Suzuki N, Ikejiri M, Takagi A, Ikawa M, Kojima T, Kunishima S, Kiyoi H, Naoe T, Matsushita T, Maruyama M. Rhof promotes murine marginal zone B cell development. Nagoya J Med Sci, 2014 Aug;76(3-4):293-305.
    4. Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K, Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F, Suzushima H, Kato Y, Miwa H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia, 2014 Aug;28(8):1586-95.
    5. Shimada K, Tomita A, Saito S, Kiyoi H. Effectiveness of ofatumumab to rituximab resistant CLL/SLL cells with reduced CD20 protein expression. Br J Haematol, 2014 Aug;166(3):455-7.
    6. Terakura S, Nishida T, Inamoto Y, Ohashi H, Naoe T, Murata M. Successful unrelated cord blood transplantation for adult acquired aplastic anemia using reduced intensity conditioning without ATG. Immunol Lett, 2014 Jul;160(1):99-101.
    7. Nishiwaki S, Nakayama T, Murata M, Nishida T, Terakura S, Saito S, Kato T, Mizuno H, Imahashi N, Seto A, Ozawa Y, Miyamura K, Ito M, Takeshita K, Kato H, Toyokuni S, Nagao K, Ueda R, Naoe T. Dexamethasone palmitate ameliorates macrophages-rich graft-versus-host disease by inhibiting macrophage functions. PLoS One, 2014 May; 9(5):e96252.
    8. Kato T, Nishida T, Ito Y, Murase M, Murata M, Naoe T. Correlations of programmed death 1 expression and serum IL-6 level with exhaustion of cytomegalovirus-specific T cells after allogeneic hematopoietic stem cell transplantation. Cell Immunol, 2014 Mar-Apr;288(1-2):53-59.
    9. Murata M, Nishida T, Taniguchi S, Ohashi K, Ogawa H, Fukuda T, Mori T, Kobayashi H, Nakaseko C, Yamagata N, Morishima Y, Nagamura-Inoue T, Sakamaki H, Atsuta Y, Suzuki R, Naoe T. Allogeneic transplantation for primary myelofibrosis with bone marrow, peripheral blood, or umbilical cord blood: An analysis of the JSHCT. Bone Marrow Transplant, 2014 Mar;49(3):355-60.
    10. Yasuda T, Ueno T, Fukumura K, Yamato A, Ando M, Yamaguchi H, Soda M, Kawazu M, Sai E, Yamashita Y, Murata M, Kiyoi H, Naoe T, Mano H. Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation. Leukemia, 2014 Feb;28(2):426-8.
    11. Tokunaga T, Tomita A, Sugimoto K, Shimada K, Iriyama C, Hirose T, Shirahata-Adachi M, Suzuki Y, Mizuno H, Kiyoi H, Asano N, Nakamura S, Kinoshita T, Naoe T.\tDe novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. Cancer Sci, 2014 Jan;105(1):35-43.
  • 2013
    1. Imahashi N, Nishida T, Ito Y, Kawada JI, Nakazawa Y, Toji S, Suzuki S, Terakura S, Kato T, Murata M, Naoe T. Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy.\tMol Immunol, 2013 Dec;56(4):399-405.
    2. Hayakawa F, Sugimoto K, Harada Y, Hashimoto N, Ohi N, Kurahashi S, Naoe T.\t A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J, 2013 Nov;3:e166.
    3. Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, Mori T, Taniguchi S, Eto T, Ohashi K, Hino M, Inoue M, Ogawa H, Atsuta Y, Nagamura-Inoue T, Yabe H, Morishima Y, Sakamaki H, Suzuki R. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD working group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant, 2013 Aug;19(8):1183-9.
    4. Suzuki N, Kunishima S, Ikejiri M, Maruyama S, Sone M, Takagi A, Ikawa M, Okabe M, Kojima T, Saito H, Naoe T, Matsushita T. Establishment of Mouse Model of MYH9 Disorders: Heterozygous R702C Mutation Provokes Macrothrombocytopenia with Leukocyte Inclusion Bodies, Renal Glomerulosclerosis and Hearing Disability. PLoS One, 2013 Aug;8(8):e71187.
    5. Niimi K, Kiyoi H, Ishikawa Y, Hayakawa F, Kurahashi S, Kihara R, Tomita A, Naoe T. GATA2 zinc finger 2 mutation found in acute myeloid leukemia impairs myeloid differentiation. Leukemia Research Reports, 2013 Mar 19;2(1):21-5.
    6. Yasuda T, Suzuki R, Ishikawa Y, Terakura S, Inamoto Y, Yanada M, Nagai H, Ozawa Y, Ozeki K, Atsuta Y, Emi N, Naoe T. Randomized controlled trial comparing ciprofloxacin and cefepime in febrile neutropenic patients with hematological malignancies. Int J Infect Dis, 2013 Jun;17(6):e385-90.
    7. Tomita A, Kiyoi H, Naoe T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol\t, 2013 Jun;97(6):717-25.
  • 2012
    1. Mizuno H, Nakayama T, Miyata Y, Saito S, Nishiwaki S, Nakao N, Takeshita K, Naoe T. Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib. Leukemia, 2012 Oct;26(10):2269-76.
    2. Minami Y, Abe A, Minami M, Kitamura K, Hiraga J, Mizuno S, Ymamoto K, Sawa M, Inagaki Y, Miyamura K, Naoe T. Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors. Leukemia, 2012 Sep;26(9):2142-3.
    3. Kuwatsuka Y, Kohno A, Terakura S, Saito S, Shimada K, Yasuda T, Inamoto Y, Miyamura K, Sawa M, Murata M, Karasuno T, Taniguchi S, Nagafuji K, Atsuta Y, Suzuki R, Fukumoto M, Naoe T, Morishita Y; Nagoya Blood and Marrow Transplantation Group. Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy.Cancer Sci, 2012 Sep;103(9):1688-94.
    4. Shimada K, Tomita A, Minami Y, Abe A, Hind CK, Kiyoi H, Cragg MS, Naoe T. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. Exp Hematol, 2012 Sep;40(9):724-737.
    5. Nishiwaki S, Nakayama T, Saito S, Mizuno H, Ozaki T, Takahashi Y, Maruyama S, Nishida T, Murata M, Kojima S, Naoe T. Efficacy and safety of human adipose tissue-derived mesenchymal stem cells for supporting hematopoiesis. Int J Hematol, 2012 Sep;96(3):295-300.
    6. Sugimoto T, Tomita A, Abe A, Iriyama C, Kiyoi H, Naoe T. Chimeric antisense RNA derived from chromosomal translocation modulates target gene expression. Haematologica, 2012 Aug;97(8):1278-80.
    7. Tomita A, Shirasugi Y, Ito T, Tsurumi H, Naoe T. Extravascular hemolytic attack after eculizumab therapy for paroxysmal nocturnal hemoglobinuria. Ann Hematol, 2012 Jul;91(7):1139-41.
    8. Watanabe K, Minami Y, Ozawa Y, Miyamura K, Naoe T. T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports. Anticancer Res, 2012 May;32(5):1779-83.
    9. Kajiguchi T, Katsumi A, Tanizaki R, Kiyoi H, Naoe T. Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-catenin. Kajiguchi T, Katsumi A, Tanizaki R, Kiyoi H, Naoe T. Eur J Haematol, 2012 Apr;88(4):314-20.
    10. Nishiwaki S, Nakayama T, Murata M, Nishida T, Sugimoto K, Saito S, Kato T, Mizuno H, Imahashi N, Seto A, Ozawa Y, Goto T, Koyama D, Yokohata E, Kubota N, Kamoshita S, Miyamura K, Matsumoto K, Ito M, Naoe T. Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy. Int J Hematol, 2012 Apr;95(4):428-33.
    11. Kato T, Terakura S, Murata M, Sugimoto K, Murase M, Iriyama C, Tomita A, Abe A, Suzuki M, Nishida T, Naoe T. Escape of leukemia blasts from HLA-specific CTL pressure in a recipient of HLA one locus-mismatched bone marrow transplantation. Cell Immunol, 2012 Mar-Apr;276(1-2):75-82.
    12. Iriyama C, Tomita A, Hoshino H, Adachi-Shirahata M, Furukawa-Hibi Y, Yamada K, Kiyoi H, Naoe T. Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome. Biochem Biophys Res Commun, 2012 Mar 23;419(4):662-9.
    13. Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, Tanimoto M, Iwasaki T, Isoda A, Sakai A, Kobayashi H, Kitamura K, Matsue K, Taniwaki M, Tamashima S, Saburi Y, Masunari T, Naoe T, Nakamura S, Kinoshita T. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood, 2012 Mar 22;119(12):2837-43.
    14. Yasuda T, Hayakawa F, Kurahashi S, Sugimoto K, Minami Y, Tomita A, Naoe T. B cell receptor-ERK1/2 signal cancels PAX5-dependent repression of BLIMP1 through PAX5 phosphorylation: a mechanism of antigen-triggering plasma cell differentiation. J Immunol, 2012 Jun 15;188(12):6127-34.
  • 2011
    1. Murase M, Nishida T, Onizuka M, Inamoto Y, Sugimoto K, Imahashi N, Murata M, Miyamura K, Kodera Y, Inoko H, Naoe T. Cytotoxic T-lymphocyte antigen 4 haplotype correlates with relapse and survival after allogeneic hematopoietic SCT. Bone Marrow Transplant, 2011 Nov;46(11):1444-9.
    2. Saito S, Nakayama T, Hashimoto N, Miyata Y, Egashira K, Nakao N, Nishiwaki S, Hasegawa M, Hasegawa Y, Naoe T. Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage. Am J Pathol, 2011 Sep;179(3):1088-94.
    3. Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood. 2011 Aug 11;118(6):1600-9.
    4. Terakura S, Atsuta Y, Sawa M, Ohashi H, Kato T, Nishiwaki S, Imahashi N, Yasuda T, Murata M, Miyamura K, Suzuki R, Naoe T, Ito T, Morishita Y. A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. Ann Oncol. 2011 Aug;22(8):1865-71.
    5. Ishikawa Y, Kiyoi H, Naoe T. Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia. Leukemia Res, 2011 May;35(5):685-8.
    6. Kurahashi S, Hayakawa F, Miyata Y, Yasuda T, Minami Y, Tsuzuki S, Abe A, Naoe T. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML. Oncogene, 2011 Apr 14;30(15):1822-30.
    7. Katsumi A, Kiyoi H, Abe A, Tanizaki R, Iwasaki T, Kobayashi M, Matsushita T, Senga T, Kohno T, Kojima T, Kaibuchi K, Hamaguchi M, Naoe T. FLT3/ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signaling. Eur J Haematol, 2011 Mar;86(3):191-8.
    8. Sakai K, Ishikawa Y, Mori Y, Kobayashi M, Iriyama C, Ozawa Y, Suzuki T, Minami Y, Ishikawa K, Kaneda N, Naoe T, Kiyoi H. A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib-resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. Int J Hematol, 2011 Feb;93(2):237-42.
  • 2010
    1. Tsujimura A, Kiyoi H, Shiotsu Y, Ishikawa Y, Mori Y, Ishida H, Toki T, Ito E, Naoe T. Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia. Int J Hematol, 2010 Nov;92(4):624-33.
    2. Minami Y, Kajiguchi T, Abe A, Ohno T, Kiyoi H, Naoe T. Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment. Int J Hematol, 2010 Nov;92(4):664-6.
    3. Ishikawa Y, Kiyoi H, Watanabe K, Miyamura K, Nakano Y, Kitamura K, Kohno A, Sugiura I, Yokozawa T, Hanamura A, Yamamoto K, Iida H, Emi N, Suzuki R, Ohnishi K, Naoe T. Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci, 2010 Oct;101(10):2186-92.
    4. Nakao N, Nakayama T, Yahata T, Muguruma Y, Saito S, Miyata Y, Yamamoto K, Naoe T. Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. Am J Pathol, 2010 Aug;177(2):547-54.
    5. Suzuki M, Abe A, Imagama S, Nomura Y, Tanizaki R, Minami Y, Hayakawa F, Ito Y, Katsumi A, Yamamoto K, Emi N, Kiyoi H, Naoe T. BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. Eur J Haematol, 2010 Mar;84(3):229-38.
    6. Tanizaki R, Nomura Y, Miyata Y, Minami Y, Abe A, Hanamura A, Sawa M, Murata M, Kiyoi H, Matsushita T, Naoe T. Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD/SCID/IL-2Rgammac-/- mice. Cancer Sci, 2010 Mar;101(3):631-8.
    7. Inamoto Y, Murata M, Katsumi A, Kuwatsuka Y, Tsujimura A, Ishikawa Y, Sugimoto K, Onizuka M, Terakura S, Nishida T, Kanie T, Taji H, Iida H, Suzuki R, Abe A, Kiyoi H, Matsushita T, Miyamura K, Kodera Y, Naoe T. Donor single nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD. Bone Marrow Transplant, 2010 Feb;45(2):363-9.
    8. Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, Niitsu N, Miwa H, Asaoku H, Kosugi H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Yamamoto K, Yamaguchi M, Nakamura S, Naoe T, Kinoshita T; IVL Study Group in Japan. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci, 2010 Jun;101(6):1480-6.

Research Keywords

leukemia,malignant lymphoma,multiple myeloma,myelodysplastic syndrome,aplastic anemia,hemolytic anemia,idiopathic thrombocytopenic purpura,hemophilia,von Willebrand disease,Gene mutations,chromosomal abnormalities,molecularly targeted drugs,kinase inhibitors,antibody therapeutic drugs,immunotherapy,transplantation immunity,differentiation-inducing therapy,epigenetics

Recruitment of students to the master’s and doctoral courses

 In the Department of Hematology and Oncology, we aim to advance understanding of molecular pathology in blood disease, develop new diagnostic and treatment methods, and promote high quality clinical research that can be used in evidence-based medicine. The Department’s graduate students work intensely to produce original research findings to present to the world with the ultimate goal of enabling patients to regain their health. Each project is executed together with a project leader who possesses advanced research skills, and we have a system to provide consistent guidance from carrying out the research to publishing the results. We are recruiting graduate students who move these researches forward. People with interest in the master’s and doctoral courses in the Department of Hematology and Oncology are encouraged to contact us. Program tours are available as needed.